Chris Polman, Free University of Amsterdam
Abstract N Engl J Med 2006;345:899
Despite fears that natalizumab – which reduces progression in some categories of patients with multiple sclerosis – might increased the risk of a fatal viral infection, two-year randomised study finding have now given some reassurance that patients with relapsing disease can be treated.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.